Health Care • Biotechnology: Pharmaceutical Preparations
$1.01 ▲ +0.08
(+8.05%)
MKT CAP: $6.1M • VOL: 29.6K
52W L $1 52W H $9
ROARABLE / RQD
E • 32/100
PIOTROSKI
2 / 9
XCUR // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $500.0K | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$4.2M | -$12.2M | -$15.0M |
| Operating Margin % | — | -80.0% | — |
| Net Income (GAAP) | -$4.9M | -$9.7M | -$16.9M |
| EBITDA (Normalized) | -$4.2M | -$12.2M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$8.6M | -$2.9M | -$10.4M |
| Capital Expenditures (CapEx) | $1.0K | $0 | — |
| Free Cash Flow (FCF) | -$8.6M | -$2.9M | -$10.4M |
| FCF Margin % | — | -80.0% | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | — | $12.5M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $3.9M | $6.8M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR XCUR.